The effects of trimetazidine on heart rate variability in patients with heart failure;Os efeitos da trimetazidina na Variabilidade da Frequência Cardíaca (VFC) em pacientes com insuficiência cardíaca

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 2, 2009, Pages 154-158

  Gunes, Yilmaz ^a   Guntekin, Unal ^a   Tuncer, Mustafa ^a   Sahin, Musa ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Heart failure; Heart rate; Trimetazidine administration and dosage

Indexed keywords

CARVEDILOL; DIGITALIS; FUROSEMIDE; SPIRONOLACTONE; TRIMETAZIDINE;

ADD ON THERAPY; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HUMAN; MALE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 70350723522     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000800014     Document Type: Article

References (32)

1. Cohn JN, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311 (13): 819-823 (Pubitemid 14035089)
2. Nolan J, Flapan AD, Capewell S, MacDonald T, Neilson JMM, Ewing DJ. Decreased cardiac parasympathetic activity in chronic heart failure and its relation to left ventricular function. Br Heart J. 1992; 67: 482-486
3. Nolan J, Flapan AD, Goodefield NE, Prescott RJ, Bloomfield P, Neilson JMM, et al. Measurement of parasympathetic activity from 24-hour ambulatory electrocardiograms and its reproducibility and sensitivity in normal subjects, patients with symptomatic myocardial ischemia, and patients with diabetes mellitus. Am J Cardiol. 1996; 77: 154-158 (Pubitemid 26032602)
4. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S. Heart rate variability in myocardial infarction and heart failure: review. Int J Cardiol. 2007; 120: 289-296 (Pubitemid 47069569)
5. Paschoal MA, Polessi EA, Simioni FC. Evaluation of heart rate variability in trained and sedentary climacteric women. Arq Bras Cardiol. 2008; 90: 74-79
6. Pinheiro CH, Medeiros RA, Pinheiro DG, Marinho Mde J. Spontaneous respiratory modulation improves cardiovascular control in essential hypertension. Arq Bras Cardiol. 2007; 88: 651-659
7. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom Heart Failure Evaluation and Assessment of Risk Trial (UK-Heart). Circulation. 1998; 98: 1510-1516 (Pubitemid 28481667)
8. Yi G, Goldman JH, Keeling PJ, Reardon M, McKenna WJ, Malik M. Heart rate variability in idiopathic dilated cardiomyopathy: relation to disease severity and prognosis. Heart. 1997; 77: 108-114 (Pubitemid 27115791)
9. Binkley PF, Haas GJ, Starling RC, Nunziata E, Hatton PA, Leier CV, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol. 1993; 21: 655-661 (Pubitemid 23076283)
10. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert E. Changes in heart rate variability are correlated to hemodynamic improvement with chronic carvedilol therapy in heart failure. J Card Fail. 2005; 11: 693-699 (Pubitemid 41797499)
11. Ulgen MS, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol. 2001; 77: 255-262 (Pubitemid 32162118)
12. Guler N, Eryonucu B, Gunes A, Guntekin U, Tuncer M, Ozbek H. Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 2003; 17: 371-374 (Pubitemid 37500190)
13. Katz AM. Is the failing heart energy depleted? Cardiol Clin. 1998; 16: 633-644
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18: 1440-1463 (Pubitemid 41821197)
15. Bittencourt MI, Benchimol Barbosa PR, Drumond Neto C, Bedirian R, Barbosa EC, Brasil F, et al. Assessing autonomic function in hypertrophic cardiomyopathy. Arq Bras Cardiol. 2005; 85: 388-396 (Pubitemid 44670194)
16. Menezes Ada S Jr, Moreira HG, Daher MT. Analysis of heart rate variability in hypertensive patients before and after treatment with angiotensin II-converting enzyme inhibitors. Arq Bras Cardiol. 2004; 83: 169-172
17. Kleiger RE, Miller JF, Bigger JT Jr, Moss AJ. The multicenter post infarction research group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987; 59: 256-262
18. Topal E, Ozdemir R, Barutcu I, Aksoy Y, Sincer I, Akturk E, et al. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow. J Electrocardiol. 2006; 39: 211-218
19. Szabo B, van Veldhuisen DJ, van der Veer N, Brouwer J, De Graeff PA, Crijns HJ. Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol. 1997; 79 (7): 978-980 (Pubitemid 27197938)
20. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006; 48: 992-998 (Pubitemid 44292461)
21. Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol. 2007; 62: 493-499 (Pubitemid 47582642)
22. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P, et al. Short and long term beneficial effects of trimetazidine in patients with diabetes and ischaemic cardiomyopathy. Am Heart J. 2003; 146: E1-E8.
23. Birand A, Kudabierdieva GZ, Batyraliev TA, Akgul F, Usal A. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology. 1997; 48: 413-422 (Pubitemid 27255014)
24. Aronson D, Mittleman MA, Burger AJ. Measures of heart period variability as predictors of mortality in hospitalized patients with decompensated congestive heart failure. Am J Cardiol. 2004; 93: 59-63. (Pubitemid 38022034)
25. Shlyakhto EV, Almazov VV, Nifontov EM, Vakhrameyeva IV, Rudomanov OG, Zakharov DV, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs. 2002; 2: 119-124
26. Bricaud H, Brottier L, Barat JL, Combe C, Boussens B, Bonnet J. Cardioprotective effects of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drugs Ther. 1990; 4: 861-865 (Pubitemid 20294654)
27. Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin. 2003; 19: 661-672
28. Lopaschuk GD, Stanley WA, Lopaschuk CC. Metabolic approach in heart failure: the rationale for metabolic interventions. Heart Metab. 2005; 27: 5-10.
29. Fragasso G, Spoladore R, Bassanelli G, Cuko A, Montano C, Salerno A, et al. New directions in the treatment of heart failure: targeting free fatty acid oxidation. Curr Heart Fail Rep. 2007; 4: 236-242
30. Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi in the rat isolated ventricular myocyte. Br J Pharmacol. 1996; 117: 831-838 (Pubitemid 26075960)
31. Renaud JF. Internal pH, Na+, and Ca2 regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther. 1988; 1: 677-686
32. Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Heart Fail Rev. 2002; 7: 187-203. (Pubitemid 34624806)